We value speed, audacity, authenticity, grit, and empathy, and empower our teams to reimagine the status quo.
Location: United States, Tennessee, Nashville
Employees: 201-500
Total raised: $82M
Founded date: 1999
Investors 3
| Date | Name | Website |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| - | Hercules C... | htgc.com |
| - | Shepherd V... | shepherdve... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.04.2013 | Series E | $33M | - |
| 10.06.2011 | - | $45M | - |
| 25.02.2007 | - | $4M | - |
Mentions in press and media 12
| Date | Title | Description |
| 12.11.2025 | Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic Medicine | Moxie—the all-in-one growth and operating engine trusted by 600+ of the nation's fastest-growing aesthetic practices—today announced two major initiatives shaping the future of aesthetic entrepreneurship and bridge the business gap in aesth... |
| 09.09.2024 | Sirsram Medical announces NMPA approval for DAXXIFY® | Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical ... |
| 21.03.2022 | Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management | – $300 million note purchase agreement includes committed borrowings of $200 million and an additional option of uncommitted borrowings of up to $100 million – Cash runway extended into 2024 with $100 million in notes issued at closing and ... |
| 02.04.2013 | Revance Therapeutics Raises $33M in Series E Growth Financing | Revance Therapeutics, Inc., a Newark, California-based specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, raised $33m in Series E growth financing. Revance also co... |
| 02.04.2013 | Revance Therapeutics Grabs $33M Series E | NEWARK, CA, Privately held specialty biopharmaceutical company announced that it has raised $33 million of its Series E growth financing. >> Click here for more funding data on Revance Therapeutics >> To export Revance Thera... |
| 10.06.2011 | Revance Therapeutics Closes $45M Financing | Revance Therapeutics, Inc., a Newark, California-based biopharmaceutical company that has developed proprietary platform technology which enables local, targeted delivery of large macromolecules across skin, closed a $45m financing. The rou... |
| 04.01.2010 | Revance Raises $25M in Series D Financing | Revance Therapeutics, Inc., a Newark, CA-based biopharmaceutical company, announced the first $25m closing of a $35m Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII. The financing included returning invest... |
| 18.11.2008 | Revance absorbs $8M for topical Botox | Aesthetic drug developer Revance Therapeutics has landed $8 million in venture debt financing from Leader Ventures and Horizon Technology Finance. The money will be used to push its lead compound, a topical form of botulinum toxin type A (p... |
| 27.05.2008 | ReVance, topical botox company, raises $8M more | ReVance Therapeutics, a Mountain View, Calif biopharma company focused on topical botox, has raised $8 million more in financing. Backers include executives of the company, Niagra Gorge Venture Partners, Biotechnology Development Fund, Esse... |
| 13.12.2007 | Revance gets $43M for topical Botox | See our story on this Mountain View, Calif., company in Wednesday’s daily briefing at VentureBeat Life Sciences. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transform... |
Show more